Go back to News
NEWS
GA_P advises Impact Partners on Top Doctors Series B financing round
14 October, 2021
Gómez-Acebo & Pombo has advised Impact Partners on its investment in Top Doctors. The Series B financing round, led by Impact Partners and in which the Institut Català de Finances (ICF) also participated, amounted to €11.2 million.
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Top Doctors is a startup that offers a digital tool that allows users to access more than 90,000 experts in 50 medical specialties, while providing healthcare professionals with telemedicine solutions, online presence and brand image. The company expects to close the year with a turnover of 16 million euros, 30% more than in 2020. The capital increase will allow the company to consolidate its medical platform in the countries where it already operates in Europe, Latin America and the Middle East.
The GA_P team was formed by Álvaro Mateo and Rocío García de Oteyza, partner and associate in the Corporate area.
See complete article in CincoDías
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
05 Aug, 2026 
PUBLICATION
31 Jul, 2026
Automotive and Sustainable Mobility No. 31
Summary of legislative and jurisprudential developments relating to the automotive sector.
31 Jul, 2026 
PUBLICATION
08 Jul, 2026
Are company directors directly liable for torts attributable to the company?
Debt from liability in tort for third-party damage or loss arises directly against the directors, without prejudice to the fact that, pursuant to Article 38 CC, it also arises simultaneously against the company, to which the non-contractual acts or omissions of its directors are also attributed. This is so true that the liable company (in debt, for example, with the tax authorities as the person liable for the surcharge and the tax penalty owed) may bring an action for contribution against its directors after settling the debt.
08 Jul, 2026
PUBLICATION
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
23 Jun, 2026
PUBLICATION
18 Jun, 2026
Royal Decree 415/2026: key aspects of the new health technology assessment system
Royal Decree 415/2026 establishes a unified framework for the assessment of health technologies in Spain, distinguishing between the technical assessment and the administrative decision regarding funding, pricing or inclusion in the service catalogue, and incorporating the requirements of Regulation (EU) 2021/2282. The aspect that raises the most legal questions in this new piece of legislation is the connection between the assessment regulated by the Royal Decree and the procedures for funding, pricing, and inclusion in the service catalogue.
18 Jun, 2026
PUBLICATION
09 Jun, 2026
The “serious risk” of financial assistance (Supreme Court (First Chamber) Judgment of 5 May 2026)
This paper critically analyses the Supreme Court ruling of 5May 2026, which applies the prohibition on financial assistance to a case involving the sale of treasury shares with deferred payment to the shareholders of the assisting company.
09 Jun, 2026
PUBLICATION
28 May, 2026
Voluntary takeover bids and squeeze-outs
The Judgment of the Court of Justice of the European Union (Fifth Chamber) of 13 May 2026 (Korfin and Sempiola v Slovnaft, Case C-225/25) clarifies the concept of a takeover bid for the purposes of Article 2 of the 2004 Takeover Bids Directive, such that an offer made to the holders of securities of a company with a view to acquiring all or some of those securities does not fall within the concept of a takeover bid where it is made by an offeror who already controls the offeree company. Consequently, based on that court’s interpretation of the Directive’s provisions, there is no right of squeeze-out in such voluntary takeover bids.
28 May, 2026
PUBLICATION
18 May, 2026
Automotive and Sustainable Mobility No. 30
Summary of legislative and jurisprudential developments relating to the automotive sector.
18 May, 2026
PUBLICATION
30 Apr, 2026
Pharma & Healthcare No. 48
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
30 Apr, 2026
PUBLICATION
21 Apr, 2026
The 28th Corporate Regime: the EU Inc.
The Proposal for a Regulation of the European Parliament and of the Council on the 28th Regime Corporate Legal Framework – ‘EU Inc.’, dated 18 March 2026, introduces a new form of European private limited company. Originally envisaged for start-ups and scale-ups, it has been decided to allow its adoption by all companies. There is no minimum share capital requirement; shares may have no nominal value and may carry multiple voting rights, among other features. The Commission is expected to approve model articles of association so that a company can be incorporated online in less than forty-eight hours and for less than one hundred euros.
21 Apr, 2026